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ABSTRACT
Objectives To investigate the occurrence of unconﬁrmed
positive gonorrhoea results when using molecular testing
within a large population-based survey.
Design, setting and participants Between 2010
and 2012, we did a probability sample survey of 15 162
men and women aged 16–74 years in Britain. Urine from
participants aged 16–44 years reporting ≥1 lifetime sexual
partner was tested for Neisseria gonorrhoeae and
Chlamydia trachomatis using the Aptima Combo 2 (AC2)
assay, with positive or equivocal results conﬁrmed with
molecular assays using different nucleic acid targets.
Results A total of 4550 participants aged 16–44 years
had urine test results (1885 men; 2665 women). For
gonorrhoea, 18 samples initially tested positive and eight
were equivocal. Only ﬁve out of 26 conﬁrmed, giving a
positive predictive value (PPV) for the initial testing of 19%
(95% CI 4% to 34%). Most (86% (18/21)) participants
with unconﬁrmed positive results for gonorrhoea reported
zero or one sexual partner without condoms in the past
year and none had chlamydia co-infection, whereas all ﬁve
with conﬁrmed gonorrhoea reported at least two recent
sexual partners without condoms, and four had chlamydia
co-infection. The weighted prevalence for gonorrhoea
positivity fell from 0.4% (0.3% to 0.7%) after initial
screening to <0.1% (0.0% to 0.1%) after conﬁrmatory
testing. By comparison, 103 samples tested positive or
equivocal for chlamydia and 98 were conﬁrmed
(PPV=95% (91% to 99%)).
Conclusions We highlight the low PPV for gonorrhoea
of an unconﬁrmed reactive test when deploying molecular
testing in a low-prevalence population. Failure to
undertake conﬁrmatory testing in low-prevalence settings
may lead to inappropriate diagnoses, unnecessary
treatment and overestimation of population prevalence.
INTRODUCTION
Dual nucleic acid ampliﬁcation tests (NAATs) allow
simultaneous detection of Neisseria gonorrhoeae
and Chlamydia trachomatis.1 While advantageous
in some settings, the appropriate deployment of
dual NAATs is complicated by the different epi-
demiological characteristics of these infections.2
National surveillance data for gonorrhoea diagno-
ses in specialist sexual health clinics (genitourinary
medicine (GUM) clinics) show that gonorrhoea is
highly concentrated geographically and in speciﬁc
population groups in England (eg, men who have
sex with men and black Caribbeans).3 Even so, gon-
orrhoea prevalence is below 1% in around one-third
of GUM clinics (Town, Public Health England,
unpublished data). Studies in community-based set-
tings suggest that gonorrhoea prevalence ranges
from 0.3% to 1.7% outside London, and up to
4.1% in South London, but might overestimate
prevalence due to a lack of conﬁrmatory testing and/
or selection bias in the population tested.4
Using data from the third National Survey of
Sexual Attitudes and Lifestyles (Natsal-3), a repre-
sentative probability sample of British residents, we
have previously shown that chlamydia prevalence
in the sexually active general population was 1.3%
in men and 1.5% in women aged 16–44 years,
with half of chlamydia infections found in those
with only one recent partner.5 By contrast, gonor-
rhoea prevalence was below 0.1%, with infection
restricted to individuals reporting risky sexual
behaviour.5 Since the positive predictive value
(PPV) for any test decreases with lower prevalence,
testing in low prevalence areas is likely to lead to
an increased proportion of positive tests that do
not conﬁrm.6
To inform gonorrhoea testing policy, we report
the occurrence of unconﬁrmed positive gonorrhoea
results using a dual assay, uniquely linking labora-
tory ﬁndings with demographic and behavioural
data in the British sexually active population.
METHODS
Participants and survey procedures
Natsal-3 was a stratiﬁed probability sample survey
of 15 162 men and women aged 16–74 years in
Britain who were interviewed during 2010–2012.
The estimated overall response rate was 57.7% and
the cooperation rate was 65.8% (of all eligible
addresses contacted). Participants were interviewed
using computer-assisted face-to-face and self-
Field N, et al. Sex Transm Infect 2014;0:1–4. doi:10.1136/sextrans-2014-051850 1
Epidemiology
 STI Online First, published on December 15, 2014 as 10.1136/sextrans-2014-051850
Copyright Article author (or their employer) 2014. Produced by BMJ Publishing Group Ltd under licence. 
group.bmj.com on March 19, 2015 - Published by http://sti.bmj.com/Downloaded from 
completion questionnaires; further methodological details have
been described elsewhere.5 After the interview, we invited a
sample of participants aged 16–44 years to provide urine for
sexually transmitted infection (STI) testing.5 The ﬁrst 4–5 mL of
voided urine was collected with the FirstBurst device, and
posted to Public Health England for testing.
Laboratory methods
Details of urine sample preparation, testing and quality assur-
ance are available elsewhere.5 Our pre-deﬁned testing strategy
aimed to reduce the likelihood of false positives in the ﬁnal
prevalence estimates. A primary screening test for C. trachomatis
and N. gonorrhoeae was performed using the Aptima Combo 2
(AC2) assay (Hologic Gen-Probe) using the Panther platform.
Positive, equivocal or negative results were designated according
to the manufacturers’ instructions. All samples that generated a
positive or equivocal result (hereafter referred to as ‘reactive’)
were re-tested with a secondary Aptima monospeciﬁc assay for
single detection of either C. trachomatis (Aptima CT) or
N. gonorrhoeae (Aptima GC). Only samples that were reactive
with two tests were considered true positives for our initial
paper.5 However, for gonorrhoea, to explore the possibility that
true infections might be missed (eg, due to the high mutability of
the N. gonorrhoeae genome leading to loss of assay targets), all
specimens that generated reactive results using the AC2 test were
also tested using a N. gonorrhoeae-speciﬁc multiplex real-time
PCR as a further conﬁrmatory assay. The multiplex real-time
PCR, which targets the opa gene and the porA pseudogene using
the Rotorgene 5000 platform (Qiagen)7 was performed using
DNA extracted from a separate aliquot for each sample. For this
study, we deemed a ‘conﬁrmed’ infection to be one where the
initial AC2 test was reactive and any supplementary test was posi-
tive. We used an in-house Luminex-based genotyping assay to
detect human papilloma virus (HPV) types, deﬁning high-risk
(HR-HPV) types as previously described.5
Statistical analysis
Survey analyses were done in Stata V.13 accounting for
sample stratiﬁcation, clustering and weighting. Analyses were
additionally weighted for unequal urine selection probabilities
and differential urine sample response.5
RESULTS
Laboratory ﬁndings
STI test results were available from 4550 participants (2665
women; 1885 men).5 For gonorrhoea, the weighted prevalence
for a reactive test result (18 positive; 8 equivocal), using the
AC2 test, was 0.4% (95% CI 0.3% to 0.7%). No samples with
an equivocal result could be conﬁrmed with supplementary
testing. Of the 18 samples with a positive result, four tested
positive using the AGC test, and these samples also tested posi-
tive for the opa gene and porA pseudogene. A ﬁfth sample
tested negative using the AGC assay, but positive for opa and
porA. We deemed all ﬁve samples to have conﬁrmed gonor-
rhoea. The PPV for a reactive dual NAAT test was 19% (4% to
34%) among those aged 16–44 years and 29% (5% to 53%)
among those aged 16–24 years. Overall, the weighted preva-
lence for conﬁrmed gonorrhoea was <0.1% (0.0% to 0.1%).
By comparison, 103 samples were reactive for chlamydia
using the AC2 assay (three were equivocal), of which 98 con-
ﬁrmed (two were initially equivocal using the AC2 assay). The
PPV for chlamydia was 95% (91% to 99%). Among those aged
16–44 years, the weighted prevalence for a reactive test for
chlamydia was 1.3% (1.1% to 1.8%), and not different from
conﬁrmed chlamydia (1.3% (1.0% to 1.6%)).
Epidemiological ﬁndings
Of the ﬁve samples with conﬁrmed gonorrhoea, two were from
men aged 20–34 years and three were from women aged 20–24
years (table 1). Of the 21 participants with unconﬁrmed positive
gonorrhoea, 67% (47% to 87%) were women and 57% (36%
to 87%) were under 25 years. All ﬁve participants with con-
ﬁrmed gonorrhoea reported sex with two or more partners in
the past year without condoms, whereas 86% (71% to 100%)
of those with unconﬁrmed gonorrhoea reported zero or one
such partner. Two men and two women with conﬁrmed gonor-
rhoea were co-infected with chlamydia, and all ﬁve participants
with conﬁrmed gonorrhoea had at least one HPV type. None of
the participants with unconﬁrmed positive gonorrhoea was
co-infected with chlamydia.
DISCUSSION
To our knowledge, this is the ﬁrst study of its kind linking
laboratory data to epidemiological characteristics for individuals
with unconﬁrmed positive and conﬁrmed STI results in a
population-based survey. We show that most reactive screening
tests for gonorrhoea failed to conﬁrm when deploying a NAAT
test in the sexually active British general population. The PPV
for a reactive gonorrhoea result using the AC2 assay was 19%
among those aged 16–44 years, and 29% among those aged 16–
24 years, who would be eligible for screening through the
English National Chlamydia Screening Programme. This is sub-
stantially below the 90% cut-off recommended for clinical
testing algorithms in the 2014 UK gonorrhoea testing guid-
ance.8 Among the group with unconﬁrmed positive gonorrhoea,
we identiﬁed no chlamydia co-infection and few individuals
reported recent unsafe sex, whereas all those with conﬁrmed
gonorrhoea reported characteristics associated with STI acquisi-
tion and had co-infections. Overall, the prevalence of a reactive
gonorrhoea result was 0.4%, whereas the true prevalence was
<0.1%. These data illustrate that gonorrhoea testing without
conﬁrmatory strategies risks substantially overestimating popula-
tion prevalence in a population where prevalence is low.
There are several reasons why reactive NAATs might fail to
conﬁrm for gonorrhoea, even when using highly sensitive and
speciﬁc assays. The most likely explanation is the sporadic ampli-
ﬁcation of non-speciﬁc nucleic acids, but the ﬁnding might also
be due to low-load infections, cross reaction with transient non-
gonococcal Neisseria sp present in the sample or contamination
with nucleic acid from the environment.9 We used a primary
screening test with two independent supplementary tests, each
with a different nucleic acid target, to conﬁrm gonorrhoea
results. Such comprehensive laboratory testing makes it unlikely
that gonorrhoea was missed for samples with reactive NAAT
tests. Nevertheless, we did ﬁnd one sample with a false negative
result (the sample was positive with the AC2 test, negative with
the AGC monospeciﬁc assay and positive using the multiplex
real-time PCR). Overall, these data highlight difﬁculties that can
arise when interpreting NAATresults.
We did not undertake supplementary tests for samples testing
negative on the AC2 test for logistic and cost reasons. Although
our approach replicates that used by diagnostic laboratories,
using the highly sensitive AC2 assay with automated testing, it
remains possible that a small number of gonorrhoea infections
were missed. Furthermore, urine is not considered the optimum
specimen for detecting gonorrhoea in women, and the methods
used might have limited test sensitivity.5 However, the strengths
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Table 1 Prevalence of unconfirmed positive and confirmed positive Neisseria gonorrhoeae in participants aged 16–44 years, by sex
Men Women
Unconfirmed Positive* Confirmed Positive† Denominator‡ Unconfirmed Positive*
Confirmed
Positive† Denominator‡
n Per cent 95% CI n Per cent 95% CI Unweighted, weighted n Per cent 95% CI n Per cent 95% CI Unweighted, weighted
All 7 0.3 (0.1 to 0.6) 2 <0.1 (0.0 to 0.1) 1885, 2266 14 0.5 (0.3 to 1.0) 3 <0.1 (0.0 to 0.1) 2665, 2284
Age group
16–19 3 0.9 (0.3 to 3.0) 0 0.0 – 343, 234 1 0.2 (0.0 to 1.4) 0 0.0 – 395, 214
20–24 1 0.1 (0.0 to 0.8) 1 0.1 (0.0 to 0.6) 497, 391 5 0.8 (0.3 to 2.2) 3 0.2 (0.1 to 0.7) 597, 383
25–34 3 0.4 (0.1 to 1.3) 1 0.1 (0.0 to 0.4) 693, 807 5 0.4 (0.2 to 1.1) 0 0.0 – 1146, 809
35–44 0 0.0 – 0 0.0 – 352, 835 3 0.5 (0.2 to 1.8) 0 0.0 – 527, 878
No. of partners without a condom, past year
0 3 0.5 (0.1 to 1.5) 0 0.0 – 425, 494 2 0.2 (0.0 to 0.8) 0 0.0 – 469, 428
1 3 0.1 (0.0 to 0.4) 0 0.0 – 1111, 1486 10 0.6 (0.3 to 1.3) 0 0.0 – 1806, 1629
2+ 1 0.6 (0.1 to 4.0) 2 0.3 (0.1 to 1.2) 322, 264 2 0.4 (0.1 to 1.7) 3 0.4 (0.0 to 0.1) 355, 200
Co-infection in urine
Chlamydia (men & women)§ 0 0.0 – 4 1.9 (0.7 to 5.1) 98, 58
HR-HPV 0 0.0 – 1 0.2 (0.0 to 0.6) 164, 183 2 0.4 (0.1 to 1.6) 3 0.2 (0.0 to 1.2) 527, 348
Any HPV 2 0.4 (0.1 to 1.9) 2 0.2 (0.1 to 0.9) 323, 354 5 0.6 (0.2 to 1.8) 3 0.1 (0.0 to 0.4) 959, 673
Experienced urethral symptoms, past month
No 7 0.3 (0.1 to 0.6) 1 <0.1 (0.0 to 0.2) 1781, 2160 12 0.5 (0.2 to 1.0) 3 <0.1 (0.0 to 0.1) 2436, 2105
Yes 0 0.0 – 1 0.3 (0.0 to 2.1) 102, 101 2 0.9 (0.2 to 4.3) 0 0.0 - 223, 175
Attended sexual health clinic, past 5 years
No 4 0.2 (0.1 to 0.6) 1 <0.1 (0.0 to 0.2) 1328, 1790 8 0.5 (0.2 to 1.1) 1 <0.1 (0.0 to 0.1) 1852, 1766
Yes 3 0.5 (0.2 to 1.6) 1 <0.1 (0.0 to 0.5) 526, 439 6 0.6 (0.3 to 1.5) 2 0.1 (0.0 to 0.5) 788, 499
*Unconfirmed positive is a sample with a positive or equivocal dual NAAT result that was negative on two supplementary tests.
†Confirmed positive is a sample with a positive or equivocal dual NAAT result that was positive on at least one of three supplementary tests.
‡Denominator is Natsal-3 participants aged 16–44 years who reported at least one partner, ever.
§For chlamydia, men and women were combined because the denominators were too small for data to be reported by gender separately.
HR-HPV, high risk human papilloma virus; NAAT, nucleic acid amplification test.
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here lie in the size and representative nature of the sample, and
linking of laboratory ﬁndings to detailed demographic and
sexual behaviour data.
Gonorrhoea control is rightly a priority for sexual health ser-
vices.10 Antibiotic resistance, transmission of resistant strains
and the frequent occurrence among marginalised minority
groups all increase public health concern about gonorrhoea.
Our ﬁndings support policies that restrict unselected gonorrhoea
testing by avoiding testing in low-prevalence populations where
most reactive results will be unconﬁrmed.8 Although multiplex
assays represent a valuable innovation, this study raises broader
issues about appropriate use of these technologies and the
importance of considering the underlying epidemiology of each
infection. These data provide evidence that clinical management
for gonorrhoea should be based on conﬁrmatory testing strat-
egies (ie, NAATs with a different nucleic acid target), which are
essential to avoid misdiagnoses and unnecessary treatment.
Studies and surveillance undertaken without conﬁrmation
testing may substantially overestimate prevalence.
Handling editor Jackie A Cassell
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